NVX-108 is an oxygen therapeutic to treat life threatening conditions such as cancer, heart attack, stroke and hemorrhagic shock. As an emulsion of dodecafluoropentane, the product was previously approved for sale in Europe as an ultrasound contrast imaging agent. We have data to show that it is safe in human subjects and shown to be effective in animal models of ischemic/hypoxic disease. Most companies have spent $10+M get to this point. Now all we have to do is a human clinical trial.